# US 2013/0259867 A1 · Diagnosis and treatments relating to her3 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0259867 A1
- Document ID: US20130259867A1
- Status: Published application
- Kind: A1
- Application number: 13/835,532
- Filed: 2013-03-15
- Published: 2013-10-03
- Earliest claimed: 2012-03-27
- Assignees: Genentech, Inc.
- Applicants: Genentech, Inc.
- Inventors: Lukas Amler; David Shames
- Web page: https://patentgrep.com/patent/US20130259867A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/55: Fab or Fab'
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present application describes the use of NRG1 overexpression as a selection criterion for treating cancer patients with a HER3 inhibitor, such as a bispecific HER3/EGFR inhibitor, and methods of treating those patients.

## Claims

### Claim 1

A method of treating a type of cancer in a patient comprising administering a therapeutically effective amount of a HER3 inhibitor to the patient, wherein the patient, prior to administration of the HER3 inhibitor, was diagnosed with a cancer which overexpresses NRG1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient was diagnosed with a cancer expressing NRG1 at a level higher than the median level for NRG1 expression in the cancer type.

### Claim 3 (depends on 2)

The method of claim 2, wherein the patient was diagnosed with a cancer expressing NRG1 at a level which is the 60th percentile or higher for NRG1 expression in the cancer type.

### Claim 4 (depends on 2)

The method of claim 2, wherein the patient was diagnosed with a cancer expressing NRG1 at a level which is the 75th percentile or higher for NRG1 expression in the cancer type.

### Claim 5 (depends on 2)

The method of claim 2, wherein the patient was diagnosed with a cancer expressing NRG1 at a level which is the 80th percentile or higher for NRG1 expression in the cancer type.

### Claim 6 (depends on 1)

The method of claim 1, wherein the type of cancer is one which exhibits a bimodal expression profile consisting of an overexpression mode and a lack of overexpression mode.

### Claim 7 (depends on 1)

The method of claim 1, wherein the type of cancer exhibits autocrine neuregulin-induced signaling.

### Claim 8 (depends on 1)

The method of claim 1, wherein the type of cancer is head and neck squamous cell carcinoma (HNSCC).

### Claim 9 (depends on 1)

The method of claim 1, wherein the HER3 inhibitor inhibits NRG1 binding to HER3.

### Claim 10 (depends on 1)

The method of claim 1, wherein the HER3 inhibitor is an antibody.

### Claim 11 (depends on 1)

The method of claim 1, wherein the HER3 inhibitor is a bispecific HER3/EGFR inhibitor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the bispecific HER3/EGFR inhibitor is a bispecific antibody which comprises an antigen binding domain that specifically binds to HER3 and EGFR.

### Claim 13 (depends on 12)

The method of claim 12, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises
a HVR-H1 comprising the amino acid sequence LSGDWIH (SEQ ID NO: 3),
a HVR-H2 comprising the amino acid sequence VGEISAAGGYTD (SEQ ID NO: 4),
a HVR-H3 comprising the amino acid sequence ARESRVSFEAAMDY (SEQ ID NO: 5), and
a HVR-L1 comprising the amino acid sequence NIATDVA (SEQ ID NO: 6),
a HVR-L2 comprising the amino acid sequence SASF (SEQ ID NO: 7), and
a HVR-L3 comprising the amino acid sequence SEPEPYT (SEQ ID NO: 8).

### Claim 14 (depends on 13)

The method of claim 13, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2.

### Claim 15 (depends on 12)

The method of claim 12, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain of SEQ ID NO: 2.

### Claim 16 (depends on 1)

The method of claim 1, wherein the diagnosis comprised determining the expression level of NRG1 in a sample from the patient's cancer and quantifying the expression level of NRG1 in the sample relative to the expression level of one or both of AL-137727 and VPS33B in the sample.

### Claim 17

A method of treating head and neck squamous cell carcinoma (HNSCC) in a patient comprising administering a therapeutically effective amount of a bispecific HER3/EGFR inhibitor to the patient, wherein the patient, prior to administration of the bispecific HER3/EGFR inhibitor, was diagnosed with a HNSCC which overexpresses NRG1.

### Claim 18 (depends on 17)

The method of claim 17, wherein the bispecific HER3/EGFR inhibitor is a bispecific antibody which comprises an antigen binding domain that specifically binds to HER3 and EGFR.

### Claim 19 (depends on 17)

The method of claim 17, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises
a HVR-H1 comprising the amino acid sequence LSGDWIH (SEQ ID NO: 3),
a HVR-H2 comprising the amino acid sequence VGEISAAGGYTD (SEQ ID NO: 4), and
a HVR-H3 comprising the amino acid sequence ARESRVSFEAAMDY (SEQ ID NO: 5), and
a HVR-L1 comprising the amino acid sequence NIATDVA (SEQ ID NO: 6),
a HVR-L2 comprising the amino acid sequence SASF (SEQ ID NO: 7), and
a HVR-L3 comprising the amino acid sequence SEPEPYT (SEQ ID NO: 8).

### Claim 20 (depends on 19)

The method of claim 19, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2.

### Claim 21 (depends on 18)

The method of claim 18, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain sequence of SEQ ID NO: 2.

### Claim 22 (depends on 17)

The method of claim 17, wherein the diagnosis comprised determining the expression level of NRG1 in a sample from the patient's HNSCC and quantifying the expression level of NRG1 in the sample relative to the expression level of one or both of AL-137727 and VPS33B in the sample.

### Claim 23

A method for selecting a therapy for a patient with a type of cancer which exhibits autocrine neuregulin-induced signaling comprising determining neuregulin 1 (NRG1) expression in a cancer sample from the patient and selecting a HER3 inhibitor for therapy if the cancer sample overexpresses NRG1.

### Claim 24 (depends on 23)

The method of claim 23, wherein the cancer sample expresses NRG1 at a level higher than the median level for NRG1 expression in the cancer type.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cancer sample expresses NRG1 at a level which is the 60th percentile or higher for NRG1 expression in the cancer type.

### Claim 26 (depends on 24)

The method of claim 24, wherein the cancer sample expresses NRG1 at a level which is the 75th percentile or higher for NRG1 expression in the cancer type.

### Claim 27 (depends on 24)

The method of claim 24, wherein the cancer sample expresses NRG1 at a level which is the 80th percentile or higher for NRG1 expression in the cancer type.

### Claim 28 (depends on 23)

The method of claim 23, wherein the type of cancer is one which exhibits a bimodal expression profile consisting of an overexpression mode and a lack of overexpression mode.

### Claim 29 (depends on 23)

The method of claim 23, wherein the type of cancer is head and neck squamous cell carcinoma (HNSCC)

### Claim 30 (depends on 23)

The method of claim 23, wherein the HER3 inhibitor inhibits NRG1 binding to HER3.

### Claim 31 (depends on 23)

The method of claim 23, wherein the HER3 inhibitor is an antibody.

### Claim 32 (depends on 31)

The method of claim 31, wherein the HER3 inhibitor is a bispecific HER3/EGFR inhibitor.

### Claim 33 (depends on 32)

The method of claim 32, wherein the bispecific HER3/EGFR inhibitor is a bispecific antibody which comprises an antigen binding domain that specifically binds to HER3 and EGFR.

### Claim 34 (depends on 33)

The method of claim 33, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises
a HVR-H1 comprising the amino acid sequence LSGDWIH (SEQ ID NO: 3),
a HVR-H2 comprising the amino acid sequence VGEISAAGGYTD (SEQ ID NO: 4), and
a HVR-H3 comprising the amino acid sequence ARESRVSFEAAMDY (SEQ ID NO: 5), and
a HVR-L1 comprising the amino acid sequence NIATDVA (SEQ ID NO: 6),
a HVR-L2 comprising the amino acid sequence SASF (SEQ ID NO: 7), and
a HVR-L3 comprising the amino acid sequence SEPEPYT (SEQ ID NO: 8).

### Claim 35 (depends on 34)

The method of claim 34, wherein the antigen binding domain that specifically binds to HER3 and EGFR comprises a heavy chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 1 and a light chain variable domain having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 2.

### Claim 36 (depends on 33)

The method of claim 33, wherein the bispecific antibody comprises a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain sequence of SEQ ID NO: 2.

### Claim 37 (depends on 23)

The method of claim 23, wherein NRG1 expression has been determined using polymerase chain reaction (PCR).

### Claim 38 (depends on 37)

The method of claim 37, wherein the PCR is quantitative real time polymerase chain reaction (qRT-PCR).

### Claim 39 (depends on 23)

The method of claim 23, wherein NRG1 expression has been determined using IHC.

### Claim 40 (depends on 23)

The method of claim 23, wherein the determining the NRG1 expression in the HNSCC sample comprises determining the expression level of NRG1 in the sample and quantifying the expression level of NRG1 in the sample relative to the expression level of one or both of AL-137727 and VPS33B in the sample.

### Claim 41 (depends on 23)

The method of claim 23, further comprising administering a therapeutically effective amount of the HER3 inhibitor to the patient.

### Claim 42

A method of quantifying NRG1 expression level in a cancer sample comprising:
determining the expression level of NRG1 in the sample, and
quantifying the expression level of NRG1 in the sample relative to the expression level of one or both of AL-137727 and VPS33B in the sample.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cancer exhibits autocrine neuregulin-induced signaling.

### Claim 44 (depends on 42)

The method of claim 42, wherein the cancer is head and neck squamous cell carcinoma (HNSCC).

### Claim 45 (depends on 42)

The method of claim 42, wherein the expression level of NRG1 and the expression level of the one or both of AL-137727 and VPS33B is determined using polymerase chain reaction (PCR).

### Claim 46 (depends on 45)

The method of claim 45, wherein the PCR is quantitative real time polymerase chain reaction (qRT-PCR).

### Claim 47 (depends on 42)

The method of claim 42, wherein the expression level of NRG1 and the expression level of the one or both of AL-137727 and VPS33B is determined using immunohistochemistry (IHC).
